Post-Dengue Vasculitis in children, diagnostic during pandemic COVID-19

Authors

  • Laura E. Alvaré Alvaré
  • Danusia Felipe Mallea
  • Mairaly Porta Díaz
  • Alena Salvato Dueñas

Keywords:

dengue, vasculitis, maculopapilar- erythematous rashes, Covid-19

Abstract

Introduction: Dengue is an infectious disease, endemic to Asia, Africa, Latin America and the Caribbean. It is caused by an RNA virus of the Flaviviridae family, identified as DEN 01,02,03,04.

Objective: To describe the process of vasculitis in children in the post-acute phase after Dengue, ruling out a Covid-19 infection.

Case reports: There are three reported clinical cases in adolescent patients: two males and one female, all residents of the municipality of Playa in Havana. They started with a fever, headache, myalgia and skin rash, diagnosed as dengue by positive IgM, which, after the clinical and laboratory manifestations had seemingly disappeared 7 and 8 days after the acute phase, started to show merging maculopapilar and erythematous rashes on lower limbs, diagnosed as vasculitis. For differential diagnosis with Covid-19, a real time PCR and antigen test were performed which tested negative.

Conclusion: All three reported cases presented dengue related vasculitis in the post-acute phase, not related to Covid-19.

Downloads

How to Cite

1.
Alvaré Alvaré LE, Felipe Mallea D, Porta Díaz M, Salvato Dueñas A. Post-Dengue Vasculitis in children, diagnostic during pandemic COVID-19. Invest Medicoquir [Internet]. 2022 Dec. 31 [cited 2025 Dec. 19];15(1):e809. Available from: https://revcimeq.sld.cu/index.php/imq/article/view/809

Issue

Vol. 15 No. 1 (2023): January-June

Section

Case presentation

License

The authors retain copyright and all unrestricted publication rights.

Medicoquirúrgicas Research is licensed under the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0) and follows the SciELO Publishing Schema (SciELO PS) for publishing in XML format.

You are free to:

  • Share — copy and redistribute the material in any medium or format.
  • Adapt — remix, transform, and build upon the material.

The license cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do this in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Non-Commercial — You may not use the material for commercial purposes.
No Additional Restrictions — You may not apply legal terms or technological measures that legally restrict others from making any use permitted by the license.

Notices:

You do not have to comply with the license for elements of the material in the public domain or where their use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all the permissions you need for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.